BMB Reports is a distinguished open-access journal published by the Korean Society of Biochemistry & Molecular Biology since 2008, making significant contributions to the fields of biochemistry, molecular biology, and medicine. With a current impact factor that positions it in the Q2 category for Biochemistry and Q1 for Miscellaneous Medicine, this journal supports a wide dissemination of high-quality research findings, fostering robust dialogue among researchers, professionals, and students alike. Based in Seoul, South Korea, BMB Reports aims to publish innovative studies that advance our understanding of biochemical and molecular processes, thus shaping the future of health and medicine. The journal's commitment to open access enhances the visibility of its articles, allowing for greater accessibility and engagement in the scientific community. With notable rankings in both the Biochemistry and Molecular Biology categories, BMB Reports stands as a vital resource for those seeking to stay at the forefront of research in these rapidly evolving disciplines.

Life Science Alliance, published by LIFE SCIENCE ALLIANCE LLC, is a premier open access journal that has been making significant contributions to the fields of Biochemistry, Genetics and Molecular Biology, Ecology, Health, Toxicology and Mutagenesis, and Plant Science since its inception in 2018. With an impressive ranking in Scopus, including Q1 quartile positions and high percentiles in relevant categories, this journal is a vital resource for researchers, professionals, and students alike who seek to advance knowledge and innovation in life sciences. The journal operates on an open access model, ensuring that research findings are freely available to the global scientific community, thereby enhancing the visibility and impact of published work. With a commitment to fostering collaboration and disseminating high-quality research, Life Science Alliance serves as an essential platform for the promotion and exchange of scientific knowledge, aiming to bridge gaps and stimulate discussions across multiple disciplines.

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

AIMS Molecular Science is a premier open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to the advancement and dissemination of high-quality research in the field of molecular science. Since its inception in 2014, this journal has established itself as a vital platform for researchers and professionals aiming to share their findings in molecular biology, chemistry, and interdisciplinary studies related to these domains. With an increasing focus on the accessibility of scientific knowledge, AIMS Molecular Science supports the open-access movement, ensuring that all published articles are freely available to the global research community. The journal emphasizes originality and significance in research, promoting innovative scientific methodologies and applications. By fostering collaboration and dialogue among scientists, AIMS Molecular Science plays a crucial role in advancing understanding and stimulating progress in molecular sciences.

Biology Direct is a leading open-access journal published by BMC, dedicated to disseminating groundbreaking research in the fields of biological sciences. Since its inception in 2006, the journal has emerged as a pivotal platform for scholars, researchers, and practitioners, providing unrestricted access to high-quality, peer-reviewed articles that cover a wide spectrum of topics, including biochemistry, ecology, and applied mathematics. With an impressive ranking in the first quartile across multiple scientific categories, including Agricultural and Biological Sciences and Biochemistry, Genetics, and Molecular Biology, Biology Direct is recognized for its rigorous standards and impactful contributions within the academic community. The journal's open-access model ensures that research findings reach a global audience, fostering collaboration and innovation. Researchers and students looking to stay ahead in the rapidly evolving biological sciences will find Biology Direct an invaluable resource for knowledge and insight.

The BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, published by the ASSOC BRAS DIVULG CIENTIFICA, serves as a vital platform for the dissemination of cutting-edge research in the fields of medicine and biological sciences. With an ISSN of 0100-879X and E-ISSN 1414-431X, this Open Access journal has been championing free access to vital scientific knowledge since 1997. It is indexed in Scopus with notable rankings across various disciplines, including a rank of #131 in General Medicine (79th percentile) and #20 in Pharmacology, Toxicology, and Pharmaceutics (75th percentile). Covering a broad scope of topics, the journal primarily focuses on areas such as biochemistry, biophysics, immunology, neuroscience, and physiology, with a commendable categorization of Q2 and Q3 quartiles for several relevant fields in 2023. Through its commitment to high-quality research and robust peer review processes, the journal not only consolidates its reputation within the academic community but also significantly contributes to the enhancement of scientific knowledge and innovation in Brazil and beyond. Researchers, professionals, and students will find an invaluable resource in this journal, which is pivotal for those looking to stay abreast of the latest developments in medical and biological research.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.